Donald W. Kufe

Dana-Farber Cancer Institute

NIH Rank #1910
  • R01 Holder
  • Top 10% Funded
  • Early Career
  • Diverse Portfolio

NIH Funding · FY2024

Total Funding
$3.6M
Fiscal year 2024
Grants Awarded
4
Active NIH grants
National Rank
#1,910
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $3.6M across 4 grants · National rank #1910.

Top grants by award amount

Donald W. Kufe's NIH grant portfolio, ranked by award amount.

  • 5UM1CA186709-08UM1
    Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)
    $2M
    award amount
  • 1R01CA282437-01A1R01
    Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancer
    $735K
    award amount
  • 2R01CA097098-20A1R01
    Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer
    $466.6K
    award amount
  • 1R21CA289134-01R21
    MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer
    $450.4K
    award amount

Affiliations

Institutions that have administered grants for Donald W. Kufe.

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    Dana-Farber Cancer Institute
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #1910
  6. 2024
    Entered Top 25% Nationally
    Ranked #1910
  7. 2024
    Entered Top 10% Nationally
    Ranked #1910
  8. 2024
    Multi-Institutional Research
    Awards at 2 institutions